Oscar Health, Inc. (NASDAQ: OSCR) disclosed a set of insider transactions involving Chief Executive Officer Mark T. Bertolini, according to a recent Form 4 filing with the Securities and Exchange Commission. Bertolini acquired 1,000,000 shares of the company's Class A Common Stock at $11.92 per share, for a total outlay of $11,920,000.
At the same time, the filing indicates that 1,000,001 shares of Class A Common Stock were disposed of at the identical price of $11.92, producing gross proceeds of $11,920,011. Those shares were withheld by the issuer to satisfy tax obligations arising from the settlement of performance stock units. The same disclosure shows that 5,733,334 performance stock units were converted into Class A Common Stock as part of the settlement process.
Market movement since the filing has been positive for the stock. Oscar Health's share price has climbed to $12.97, delivering an 11% return over the past week measured from the transaction price of $11.92. Independent valuation data noted by InvestingPro places a Fair Value for Oscar Health at $15.87, a level above recent trading but below some analyst targets.
Investor attention to the company's longer-term prospects is also reflected in analyst forecasts and coverage. InvestingPro Tips referenced in the filing indicate analysts expect the company to achieve profitability in the coming years, with earnings per share projected at $0.77 for 2026. Oscar Health is additionally listed among more than 1,400 U.S. equities covered by InvestingPro's Pro Research Reports.
These technical and valuation signals arrive against a backdrop of disappointing reported results for the fourth quarter of 2025. Oscar Health reported an earnings per share loss of -$1.24, missing the consensus estimate of -$0.89. Revenue for the period was $2.81 billion, short of the anticipated $3.11 billion.
Despite those near-term financial misses, some sell-side commentary has turned constructive. Raymond James upgraded the stock from Market Perform to Outperform and assigned a price target of $18.00. The firm cited attractive relative valuation as margins recover in the Affordable Care Act exchange market and characterized Oscar Health as "the best house in a tough neighborhood."
The combination of insider buying, conversion of performance stock units, valuation assessments from InvestingPro, and an upgraded sell-side view provides a mixed set of signals for investors assessing Oscar Health's capital structure and operating trajectory.
Summary
Oscar Health's CEO purchased 1,000,000 Class A shares at $11.92 per share while 1,000,001 shares were withheld to cover taxes related to the settlement of performance stock units. The company converted 5,733,334 performance stock units into Class A Common Stock. The stock rose to $12.97, up 11% over the past week. InvestingPro's Fair Value is $15.87, and analysts project EPS of $0.77 for 2026. The company reported Q4 2025 EPS of -$1.24 on revenue of $2.81 billion, missing estimates, and Raymond James upgraded the stock with an $18.00 price target.
Key points
- Insider activity: CEO Mark T. Bertolini purchased 1,000,000 Class A shares at $11.92 each and had 1,000,001 shares withheld to satisfy tax obligations tied to performance stock units - this impacts company equity structure and insider ownership signals.
- Performance unit conversion: 5,733,334 performance stock units were converted into Class A Common Stock, increasing the outstanding share count tied to equity compensation.
- Market and analyst signals: The share price rose to $12.97 (an 11% weekly gain), InvestingPro assigns a Fair Value of $15.87, and Raymond James upgraded the stock to Outperform with an $18.00 target - relevant for health insurance equities and broader equity market valuation assessments.
Risks and uncertainties
- Near-term financial performance risk: Q4 2025 results showed a larger-than-expected loss (EPS -$1.24 versus expected -$0.89) and revenue shortfall ($2.81 billion versus $3.11 billion), which could affect investor confidence in the health insurance sector.
- Equity dilution and compensation-related flows: The conversion of 5,733,334 performance stock units into Class A Common Stock and withholding of shares for tax obligations change share counts and may influence supply-side pressure on the stock.
- Valuation dispersion: Divergent signals from valuation services and sell-side firms - InvestingPro's Fair Value of $15.87 versus Raymond James' $18.00 target - create uncertainty about the stock's appropriate market price.